研判2026！中国琥珀酸美托洛尔缓释片行业相关政策汇总、产业链图谱、销售额、竞争格局及发展趋势分析：国产化替代市场空间巨大[图]

Core Viewpoint - The market for Succinic Acid Metoprolol Sustained-Release Tablets is experiencing a decline in sales due to price reductions from centralized procurement, despite a growing demand driven by an aging population and increasing prevalence of cardiovascular diseases [1][6]. Overview - Succinic Acid Metoprolol Sustained-Release Tablets are a β1 receptor blocker developed by AstraZeneca, primarily used for treating hypertension and chronic heart failure [2]. - The drug is recommended in various hypertension treatment guidelines and is known for its long-lasting effects and improved patient compliance due to its once-daily dosing [2]. Market Policy - The pharmaceutical manufacturing industry, including Succinic Acid Metoprolol, is supported by national policies aimed at encouraging development and reforming the healthcare system [3][4]. Industry Chain - The industry chain includes upstream suppliers of raw materials and excipients, midstream manufacturers involved in research and production, and downstream distribution channels such as healthcare institutions and pharmacies [4]. Current Development - The prevalence of hypertension in China is projected to reach 370 million by 2025, indicating a steady increase in demand for Succinic Acid Metoprolol [6]. - Sales figures show a decline from 3.23 billion yuan in 2022 to an expected 2.39 billion yuan in 2024, with 1.37 billion yuan recorded in the first half of 2025 [1][6]. Competitive Landscape - AstraZeneca holds a significant market share of 63.8% in 2024, indicating substantial room for domestic companies to capture market share [8]. - Domestic companies like Hefei Heyuan Pharmaceutical and Nantong Lianya Pharmaceutical are emerging players, with Lianya's sales of Succinic Acid Metoprolol reaching 240 million yuan in the first half of 2025 [8][9]. Development Trends - The industry is expected to undergo structural changes driven by policy reforms, shifting from price competition to value competition, and focusing on product quality and safety [10][11]. - The demand for Succinic Acid Metoprolol is anticipated to grow due to an aging population and increased health awareness, with a focus on long-acting and convenient medications [11]. - Technological innovations in sustained-release formulations and cost-effective production methods are expected to enhance product competitiveness and meet diverse clinical needs [12].